Hemostatic parameters in menstrual fluid and blood plasma during the normal menstrual cycle Cyclic variation of Urokinase-Type Plasminogen Activator
Cikot, R.J.L.M.; Dorr, P.J.; Meijer, P.; Emeis, J.J.; Kluft, C.; Dooijewaard, G.
Fibrinolysis and Proteolysis 13(Suppl 1): 47-48
1999
Document Number: 521780
Document emailed within 1 workday
Related Documents
Jespersen, J.; Kluft, C. 1986: Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle Thrombosis and Haemostasis 55(3): 388-389Uchiwa, N.; Seo, K. 1976: Experimental studies on health care administration before menstruation part 1 menstrual cycle variation of urinary electrolytes and specific gravity of the students and their pre menstrual and menstrual symptoms Journal of Gakugei Tokushima University Natural Science 27: 1-13
Tonolo, G.; Ciccarese, M.; Brizzi, P.; Milia, S.; Dessole, S.; Puddu, L.; Secchi, G.; Maioli, M. 1995: Cyclical variation of plasma lipids, apolipoproteins, and lipoprotein(a) during menstrual cycle of normal women American Journal of Physiology 269(6 Pt 1): E1101-E1105
Nelles, L.; Lijnen, H.R.; Van Nuffelen, A.; Demarsin, E.; Collen, D. 1990: Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA) Thrombosis and Haemostasis 64(1): 53-60
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Koelbl, H.; Kirchheimer, J.C.; Tatra, G.; Christ, G.; Binder, B.R. 1988: Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer Obstetrics and Gynecology 72(2): 252-256
Song, S.-j.; Hu, J.-b.; Wang, H.-x.; Wen, S.-q.; Ding, M.-p.; Huang, J.-z. 2003: Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction Zhonghua Yi Xue Za Zhi 83(18): 1583-1585
Braat, E.A.; Los, P.; Rijken, D.C. 1998: The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(5): 419-427
Göser, R.; Kindler, D.; Keller, E.; Schindler, A.E. 1980: Plasma c-AMP during the normal menstrual cycle and under different hormonal treatment Gynecologic and Obstetric Investigation 11(6): 365-372
Grøndahl-Hansen, J.; Agerlin, N.; Munkholm-Larsen, P.; Bach, F.; Nielsen, L.S.; Dombernowsky, P.; Danø, K. 1988: Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer Journal of Laboratory and Clinical Medicine 111(1): 42-51
De Boer, A.; Kluft, C.; Gerloff, J.; Dooijewaard, G.; Günzler, W.A.; Beier, H.; van der Meer, F.J.; Cohen, A.F. 1993: Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects Thrombosis and Haemostasis 70(2): 320-325
De Moerloose, P.; Mermillod, N.; Amiral, J.; Reber, G. 1998: Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1 Thrombosis and Haemostasis 79(3): 554-556
Han, X.M.; Chen, Z.Q.; Mao, H.M. 1990: Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke Zhonghua Nei Ke Za Zhi 29(9): 544-546; 575-576
Gerasimov, I.G.; Prikhod'ko, E.N.; Kalutskaia, O.A.; Entin, B.V. 1994: Biochemical blood parameters in women during menstrual cycle dynamics Fiziologiia Cheloveka 20(5): 166-169
Pérez-Palacios, G.; Iramain, C.A.; Castañeda, E.; Rojo, B.; Long, D.W.; Scaglia, H.; Gual, C. 1973: Plasma profile of pituitary gonadotropins and ovarian steroids in the normal menstrual cycle Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 25(4): 305-313
Lussier-Cacan, S.; Xhignesse, M.; Desmarais, J.L.; Davignon, J.; Kafrissen, M.E.; Chapdelaine, A. 1991: Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy Metabolism, Clinical and Experimental 40(8): 849-854
Ohta, S.; Sakuragawa, N. 1999: Urokinase-type plasminogen activator (u-PA) Nihon Rinsho. Japanese Journal of Clinical Medicine 57 Suppl: 676-677
de Maat, M.P.; Dooijewaard, G.; Meijer, P.; Binder, B.R.; Keber, D.; Risberg, B.; Kluft, C.; Jespersen, J. 2001: Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 12(6): 453-458
Lengye, E.; Singh, B.; Gum, R.; Nerlov, C.; Sabichi, A.; Birrer, M.; Boyd, D. 1995: Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene Oncogene 11(12): 2639-2648
Reid, P.C.; Virtanenkari, S. 2005: Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia : a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts Bjog (Oxford. Print) 112(8): 1121-1125